• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Piramal Pharma Solutions New API Plant in Canada Now Online

    MG America Appoints Claudio Radossi as President

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Sartorius Expands Manufacturing Site in Tunisia

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Piramal Pharma Solutions New API Plant in Canada Now Online

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Grand Opening of Kodiak Sciences’ Bioconjugation Facility

    Vertex Expands Cell and Gene Therapy Footprint
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment

    WCG Appoints Sam Srivastava CEO

    AffyXell Expands Manufacturing Partnership with GenScript ProBio

    ABL and Odimma Therapeutics Enter Development Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Kyongbo Pharmaceutical

    Biosynth Carbosynth

    Aphena Pharma Solutions

    Vector Partners Limited

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Kyongbo Pharmaceutical

    Biosynth Carbosynth

    Aphena Pharma Solutions

    Vector Partners Limited

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Partnering with a CDMO for Orphan Drug Development

    Challenges and considerations for advancing rare disease drugs to market.

    Partnering with a CDMO for Orphan Drug Development
    Related CONTENT
    • CPhI North America Travel
    • DPT
    • W. R. Grace FCMS
    • Curia
    • PCI Synthesis
    Susan Billings, Vice President & Global Head of Business Development, Curia (formerly known as AMRI)09.09.21
    Developing drugs to target rare diseases (orphan drugs) is not undertaken by many pharmaceutical companies as these diseases affect a relatively small section of the population. But rare diseases can be extremely debilitating for the affected, and present a true unmet medical need.

    Over the last few years, interest in orphan drug development has grown due to efforts by advocacy groups and incentives provided by the government. For example, the Orphan Drug Act (ODA) grants a special designation to a drug targeting a rare disease, if it meets specified criteria. Orphan drug designation qualifies the sponsor for various development incentives, including shortened clinical programs, fee waivers, faster review and approval, tax credits and longer drug market exclusivities.

    According to the National Organization for Rare Disorders (NORD), more than 25 million Americans are affected by one of 7,000 rare diseases—for which 90 percent have no FDA-approved treatment. While the FDA approved 599 drugs under the ODA between its passage in 1983 and July 2020, the vast majority—75 percent—treat just one condition. Thousands more rare diseases, which NORD defines as affecting 200,000 people or less, await drug remedies.

    As more companies delve into the development of a rare disease drug, some may want to consider partnering with a contract development and manufacturing organization (CDMO) to bring potential treatments to patients faster. When embarking on this journey with a CDMO partner, it’s critical to consider a few key challenges and understand how best to overcome them.

    Working with limited time and funds
    Orphan drugs are brought to market on a highly compressed runway that’s typically 3-8 years faster than that of a traditional drug. But the quality of an orphan drug must not suffer due to taking a shorter development path—some components of chemistry, manufacturing, and controls (CMC) cannot be compressed or redone. As such, it’s a significant challenge for sponsors and their partner CDMOs to balance the risk of reduced process development and optimization with earlier access to the drug.

    Furthermore, developers usually have to work with limited funds. But orphan drugs developed on compressed timelines require more investment in CMC earlier, while the overall program risks remain high. Many smaller companies struggle with securing sufficient funds without meaningful clinical data, which is a key factor dictating funding mechanisms.

    The best way to tackle these time and money constraints is through proactive and effective communication between sponsor and CDMO, and early strategic planning. It’s critical to have a close collaboration that balances communication with overall program management of budget and timelines. On the part of the CDMO, it’s essential to be transparent about the complexity of the development process, yet resourceful and respectful of the sponsor’s needs.

    When choosing a CDMO partner, first and foremost, sponsors should consider the CDMO’s experience and technical capability to work optimally with the program funds at hand. A strong and experienced team of process chemists, engineers, analytical chemists and regulatory experts can make a significant difference in the efficiency of development, and ultimately, how quickly a process can be optimized and validated for commercialization.  

    Ensuring product availability and managing stress on the supply chain
    As sponsors move toward commercialization, the biggest challenge is appropriately forecasting and preparing for finished dosage supply requirements at launch. But the limited time available to commercialize the product stresses the supply chain. For orphan drug programs, the commercial route must be validated years in advance of the typical time it takes for a traditional drug filing.

    Under these circumstances, both the sponsor company and the CDMO may be faced with the predicament of how much optimization is actually required. To guide this understanding, sponsors should work closely with regulatory authorities, and ensure the chemical process is reliable, reproducible, robust and complies with regulatory guidelines.

    To ensure product availability at launch, sponsors must think about building out a commercial manufacturing plan early on. It’s recommended to work backwards from the intended new drug application (NDA) filing timeline to develop a manufacturing plan that involves all supply chain parties, i.e., raw material supply through finished dosage, packaging and distribution. The partner CDMO must collaborate closely with the sponsor to understand the filing timeline, patient market for the therapeutic being commercialized and estimated market forecast demand for launch and post-launch. In this way, the CDMO can effectively:
    • Plan for technology, labor and equipment/facility capacity;
    • Implement a robust supply chain of raw materials; and
    • Ensure that the manufacturing process is validated at scale.
    A few important factors that orphan drug sponsors and their CDMOs must consider when planning ahead for process development are the type of drug being made, target population and its size, and dosage. To illustrate these considerations, a good example would be making a very potent drug for a very rare disease. In this case, the patient population is narrow and the quantity of drug needed per patient dose is small, so drug production happens in small batches. As such, the process chemistry development can tolerate more risk.

    In contrast, drugs that target a larger population and are needed in higher doses require more scrutiny as significant amounts of drug are produced. The bigger the batches, the higher the potential for issues with the chemical route. This type of large-scale development can result in a great deal of pressure for the CDMO, in terms of safety and expense. To mitigate that pressure and risk, the CDMO must keep in close collaboration with the sponsor to understand key CMC decisions and develop a robust commercial route.

    No matter how well-planned a manufacturing project may be, unexpected program delays, natural disasters and shipping issues can occur, causing major stress on the supply chain. For example, the COVID-19 pandemic has hindered supply chains across the globe in various industries. Therefore, it’s crucial for any manufacturing organization to have appropriate business continuity plans established. Orphan drug sponsors and their CDMOs must have contingency planning for raw material shortages, facility changes, equipment downtime and surges in product demand.

    Curia, a global CDMO that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries, was well-prepared to face the COVID-19 pandemic due to its strong contingency planning tactics. These included dual sourcing and raw material stockpiling to assure uninterrupted supply. For example, Curia, formerly AMRI, had implemented effective dual sourcing strategies in which both sources were located in different geographies and each had its own distinct supply chain in place.

    Managing the regulatory aspects
    As product quality and patient safety are the top-most priorities for both sponsor and CDMO, CMC teams should initiate interactions with the FDA or other relevant regulatory agencies as early as possible. Proper direction from regulatory authorities can be immensely helpful for sponsors and their partner CDMOs to rapidly develop a plan for the best chemical process and efficient commercial manufacture.

    Developing an orphan drug does not always allow for sufficient time or funds to fix every single issue that comes up during manufacturing. Therefore, it’s vital to know what to prioritize. Sponsors and their CDMO must work together to identify issues requiring immediate attention and careful troubleshooting, while de-prioritizing minor issues that can be tolerated in a robust and reliable manufacturing process. CMC teams should focus only on solving the most critical process chemistry issues, while taking advantage of every learning opportunity.

    This is where experience in orphan drug development becomes important, as it will be easier for veteran teams to spot significant vulnerabilities and strike the right balance on what needs to be fixed. Proactive and clear communication between sponsor and CDMO is vital, especially related to CMC challenges.

    Conclusion
    A path to advancing a rare disease drug to market comes with its own set of challenges that drug sponsors must be aware of and prepared to address upfront, if they are to succeed in CMC development on an expedited timeline. The fastest and most pragmatic way forward may be to consult and partner with a CDMO that has the exact expertise, technical capability, and experience that is required in this arena. If choosing to go this route, sponsors should consider partnering with a CDMO that prioritizes effective communication and proficient planning, and can also offer strong regulatory knowledge and support. 
    Related Searches
    • Drug Development
    Suggested For You
    CPhI North America Travel CPhI North America Travel
    DPT DPT
    W. R. Grace FCMS W. R. Grace FCMS
    Curia Curia
    PCI Synthesis PCI Synthesis
    Seqens CDMO North America Seqens CDMO North America
    pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray
    Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate  Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    Clean Cells Expands Bioproduction Capabilities Clean Cells Expands Bioproduction Capabilities
    Hookipa Enters Clinical Collaboration & Supply Agreement with Merck & Co. Hookipa Enters Clinical Collaboration & Supply Agreement with Merck & Co.
    CEO Spotlight: Gaston Salinas, Botanical Solution Inc. CEO Spotlight: Gaston Salinas, Botanical Solution Inc.
    Lakes BioScience Signs Agreement with Cytvia Lakes BioScience Signs Agreement with Cytvia
    Samsung Biologics to Participate in Frontier 1.5D Initiative Samsung Biologics to Participate in Frontier 1.5D Initiative
    Boyds Opens US Office in PA Boyds Opens US Office in PA

    Related Content

    • CPhI North America Travel

      CPhI North America Travel

      ...
      04.21.22

    • R&D
      DPT

      DPT

      With a specialized focus on semi-solids and liquids, DPT offers pharmaceutical companies the broadest range of capabilities in the industry. From R&D formulation to commercial-scale manufacturing, small batches to large, liquids to emulsions, sterile or non-sterile, we offer clients of all sizes the most effective resources for meeting challenges.
      Stacy London, Senior Manager, Marketing & Communications 12.02.21

    • W. R. Grace FCMS

      W. R. Grace FCMS

      ...
      Stella Ip, Director Marketing Health and Life Sciences 11.23.21


    • cGMP Manufacture | Chemistry
      Curia

      Curia

      ...
      Cheryl Cook, Marketing Communications Manager 11.10.21

    • PCI Synthesis

      ...
      Norman Birnbach, PR for PCI Synthesis 10.05.21

      Trending
      • Catalent Invests $175M To Expand Mfg. Capabilities At Winchester, KY | Contract Pharma
      • Sartorius Expands Manufacturing Site In Tunisia | Contract Pharma
      • Grand Opening Of Kodiak Sciences’ Bioconjugation Facility | Contract Pharma
      • Vertex Expands Cell And Gene Therapy Footprint | Contract Pharma
      • Emergex COVID-19 Vaccine Candidate Successfully Coated Onto Zosano Micro-Needle Patch | Contract Pharma
      Breaking News
      • Piramal Pharma Solutions New API Plant in Canada Now Online
      • MG America Appoints Claudio Radossi as President
      • Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      • Sartorius Expands Manufacturing Site in Tunisia
      • BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Five PPG Facilities in Ohio Recognized for Sustainability, Health, Safety Practices
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      FDA Clears Arterys' AI Mapping and Quantification Tools
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      ÄZ Craft Luxury Haircare Products Support All Hairstyles
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nazdar celebrates 100th anniversary with refreshed brand identity
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      'Right' Hygiene Conference to be Held in June
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Cionic Expands Scientific Advisory Board
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login